A 68-year-old Indian male smoker with a 10-year history of dry AMD presents with sudden onset of metamorphopsia and central visual blurring in his right eye over the past 2 weeks. On dilated fundus examination, the macula shows scattered drusen, intraretinal hemorrhages, and lipid exudates. OCT reveals intraretinal and subretinal fluid with a hyperreflective lesion breaking through Bruch membrane. The structure marked **D** in the diagram—the grayish-green subretinal CNV membrane with associated fluid—is the defining lesion of neovascular AMD. Which of the following statements best reflects the clinical significance of this lesion in the context of AMD-related vision loss?

Question

Accepted Answer

D. Wet AMD accounts for only 10-15% of all AMD cases but is responsible for 80-90% of severe vision loss from AMD, making urgent anti-VEGF therapy essential to prevent irreversible central vision loss. ## Why option 1 is correct

The clinical anchor directly states that although wet AMD (neovascular AMD) accounts for only 10-15% of AMD cases, it is responsible for 80-90% of severe visual loss from the disease. The structure marked **D**—the grayish-green subretinal CNV membrane with subretinal/intraretinal fluid—is the pathologic hallmark of wet AMD and the defining lesion that requires urgent intravitreal anti-VEGF therapy. Without treatment, untreated wet AMD leads to legal blindness (≤20/200) within 2 years in most patients. This disproportionate burden of severe vision loss, despite being a minority of AMD cases, is the critical clinical pearl that drives urgent intervention in patients presenting with this lesion. The patient's presentation (sudden metamorphopsia, OCT findings of CNV with fluid) confirms wet AMD, mandating immediate anti-VEGF therapy.

## Why each distractor is wrong

- **Option 2**: Factually incorrect. Wet AMD accounts for only 10-15% of AMD cases, not the majority. Dry AMD (including geographic atrophy) is far more common. Additionally, wet AMD causes MORE severe vision loss than geographic atrophy, not less.
- **Option 3**: Dangerously incorrect. The CNV membrane is not benign and does not stabilize spontaneously. Without treatment, it progresses rapidly to disciform scarring and irreversible central vision loss within months to 2 years.
- **Option 4**: Incorrect management approach. AREDS2 supplementation is indicated for intermediate dry AMD to slow progression to advanced disease, but it does NOT treat existing wet AMD. Anti-VEGF therapy is the gold standard first-line treatment for wet AMD regardless of visual acuity threshold, not reserved for vision <20/60. Smoking cessation is important but is a preventive measure, not primary treatment for active CNV.

**High-Yield:** Wet AMD = 10-15% of cases but 80-90% of severe vision loss; CNV with fluid = URGENT anti-VEGF therapy to prevent irreversible blindness.

[cite: AAO Preferred Practice Pattern AMD 2024; Kanski Clinical Ophthalmology 9e Ch 14]

Answer

A. Wet AMD is primarily managed with AREDS2 supplementation and smoking cessation, with anti-VEGF therapy reserved only for cases with vision loss below 20/60

Answer

B. Wet AMD is the most common form of AMD and accounts for the majority of cases, though it causes less severe vision loss than geographic atrophy

Answer

C. The CNV membrane represents a benign finding that typically stabilizes spontaneously within 6 months without treatment in most patients

Explanation

Practice similar questions